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Since March 2019, the 
coronavirus disease 2019 
(COVID-19) pandemic has 
dominated news cycles, 
challenged politics and in-
spired scientists. Many of 
the early candidate drugs to help fight this deadly 
virus were existing anti-infective agents. Among 
them were azithromycin, hydroxychloroquine, 
lopinavir and ritonavir — drugs that are known 
to prolong the QT interval, and as a consequence, 
increase an individual’s risk of sudden cardiac 
death. Widespread use and research with these 
drugs led to a larger need to monitor electrocar-
diograms (ECG) in these patients, ideally without 
bringing COVID-19 infected patients in contact 
with healthcare personnel and other patients [1].
In the current issue of the journal, Abellas- 
-Sequeiros et al. [2] report an experience using
a hand-held ECG-recording device to measure
the QTc interval in patients with COVID-19. The
authors used the KardiaMobile6L® 6-lead ECG to
make recordings at varying frequencies in patients
who were taking azithromycin, hydroxychloro-
quine, lopinavir/ritonavir, or combinations of these
drugs. Over a mean follow-up of 6.2 ± 8.4 days,
they observed mean QTc 
interval prolongations of 
28 ms in patients taking 
two drugs and mean QTc 
interval prolongations of 
41 ms in patients taking 
3 drugs. A total of 12 of 
the 70 patients in their 
study had their therapies 
changed because of in-
creases in their QTc. The 
authors concluded that 
portable ECG-recorders are a useful and reliable 
tool for QT interval monitoring in COVID-19 
patients.
Myriad studies have now refuted the efficacy of 
azithromycin, hydroxychloroquine, and lopinavir/ri-
tonavir across the spectrum of patients who have or 
are at risk for COVID-19 [3–6]. However, the need 
for convenient and reliable ways to measure the QT 
interval persists. Several common classes of drugs 
are known to prolong the QT and are frequently 
administered in outpatient settings (Table 1) [7]. 
The authors have clearly demonstrated the feasibil-
ity of using hand-held ECG technology to monitor 
the QT interval in ambulatory patients who have 
started a new drug therapy. Clinicians should con-
sider this approach in select patients to minimize 
hospitalizations and to maximize convenience and 
compliance.
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Table 1. QT-prolonging drugs that could be 
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